← Human Trials & Peer-Reviewed Studies
Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease
Plain-language guide to PMID 15146428 (2004): clinical trial study of Angiotensin II, raynaud's.
Key Facts
- PMID
- 15146428
- Journal
- Arthritis and rheumatism
- Year
- 2004
- Study type
- Clinical Trial
- Authors
- Furspan PB et al. (3 authors)
- DOI
- 10.1002/art.20214
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Angiotensin II in the context of raynaud's.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, women only.
The response of dermal arterioles isolated from control (n = 29) and RD (n = 29) subjects to contractile and dilatory agents at 37 degrees C and 31 degrees C was characterized using the microvessel perfusion technique.
How the Study Was Run
Fluorescence immunohistochemistry was used to measure tyrosine phosphorylation.
What Was Measured
The subject headings attached to it are Adrenergic alpha-Agonists, Angiotensin II, Arterioles, Brimonidine Tartrate, Cold Temperature, Enzyme Inhibitors and Genistein.
What This Means in Plain Language
This is a clinical trial of Angiotensin II in people with raynaud's.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2004 (Arthritis and rheumatism), a journal based in United States.
More context: the Angiotensin II compound page, Raynaud's research.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.